Meiji Chemical & Pharmaceutical Announces Board Approval to Cancel Funding Loan Facility to Subsidiary Alvogen Korea Holdings Ltd.
Key facts
- Meiji Chemical & Pharmaceutical Announces Board Approval to Cancel Funding Loan Facility to Subsidiary Alvogen Korea Holdings Ltd.
- Meiji Chemical & Pharmaceutical Co., Ltd. announced that its board has approved the cancellation of a USD 15 million funding loan facility to its subsidiary, Alvogen Korea Holdings Ltd., in response to current operational conditions.
- Source: PR Times
- Date: June 26, 2026
Direct answer
Meiji Chemical & Pharmaceutical Co., Ltd. announced that its board has approved the cancellation of a USD 15 million funding loan facility to its subsidiary, Alvogen Korea Holdings Ltd., in response to current operational conditions.
- Citation
- Meiji Chemical & Pharmaceutical Announces Board Approval to Cancel Funding Loan Facility to Subsidiary Alvogen Korea Holdings Ltd. (June 26, 2026), PR Times
- Source
- PR Times
- Date
- June 26, 2026
Meiji Chemical & Pharmaceutical Co., Ltd. announced that its board has approved the cancellation of a USD 15 million funding loan facility to its subsidiary, Alvogen Korea Holdings Ltd., in response to current operational conditions.
📋 Article Processing Timeline
- 📰 Published: June 26, 2026 at 09:00
- 🔍 Collected: June 27, 2026 at 17:00 (32h 0m after Published)
- 🤖 AI Analyzed: June 27, 2026 at 18:52 (1h 51m after Collected)
1. Date of Event: 115/06/26
2. Company Name: Meiji Chemical & Pharmaceutical Co., Ltd.
3. Relationship to Company: Parent Company
4. Cross-shareholding Ratio: 100%
5. Reason for Occurrence: In alignment with the company's current operational status, the USD 15 million funding loan facility to Alvogen Korea Holdings Ltd. has been canceled.
6. Countermeasures: Not applicable
7. Other Matters to be Disclosed: As the entity involved is a publicly listed company, this material information also qualifies as a matter of significant impact on shareholders' equity or securities prices under Article 7, Clause 9 of the Enforcement Rules of the Securities Trading Act. No additional disclosures are required.
Keywords: Material Information
2. Company Name: Meiji Chemical & Pharmaceutical Co., Ltd.
3. Relationship to Company: Parent Company
4. Cross-shareholding Ratio: 100%
5. Reason for Occurrence: In alignment with the company's current operational status, the USD 15 million funding loan facility to Alvogen Korea Holdings Ltd. has been canceled.
6. Countermeasures: Not applicable
7. Other Matters to be Disclosed: As the entity involved is a publicly listed company, this material information also qualifies as a matter of significant impact on shareholders' equity or securities prices under Article 7, Clause 9 of the Enforcement Rules of the Securities Trading Act. No additional disclosures are required.
Keywords: Material Information
FAQ
What is the main purpose of this announcement?
To enhance operational transparency and financial health, protecting shareholder value.
Will Alvogen Korea continue operations?
Yes, it will operate independently and explore alternative funding options.
Impact on Taiwan's pharmaceutical industry?
May trigger broader review of intra-group financing, promoting capital efficiency.